K4 Elite
K4 Elite
A non-peptide, orally bioavailable small-molecule agonist of the GLP-1 receptor, studied as a biased partial agonist in receptor structural biology, rodent and non-human-primate models, and late-stage clinical trial programs.
Orforglipron (LY3502970, originally OWL833) is not a peptide. It is a small-molecule, orally bioavailable agonist of the glucagon-like peptide-1 receptor (GLP-1R), and it is catalogued here because it is the reference non-peptide comparator against which peptide GLP-1 receptor agonists are now benchmarked in the metabolic literature [1][5].
Its significance in the research record is that it engages a class B G protein-coupled receptor - a receptor family long considered difficult to activate with anything other than a peptide ligand - from an entirely small-molecule scaffold that survives oral administration [1].
The compound has progressed through a published Phase 1a single- and multiple-ascending-dose program and into Phase 3 trial programs in type 2 diabetes and obesity, with results reported in the New England Journal of Medicine [2][3][4].
Cryo-EM work on the active-state GLP-1R in complex with LY3502970 described a binding pocket in the upper helical bundle formed by the receptor extracellular domain, extracellular loop 2, and transmembrane helices 1, 2, 3 and 7 - a site distinct from where the endogenous peptide agonist binds. Investigators reported that the resulting receptor conformation is associated with partial agonism and with signaling bias toward G protein activation over beta-arrestin recruitment [1].
The same structural work identified an interaction with Trp33 of the receptor extracellular domain, a residue described as primate-specific, which the authors used to explain species-selective activity and which shapes how preclinical models for this compound are designed [1][5].
Kawai and colleagues solved a high-resolution structure of LY3502970 bound to the active-state GLP-1R and paired it with functional signaling assays. In humanized GLP-1R transgenic mice, oral administration was reported to lower glucose; in non-human primates, investigators reported insulinotropic and hypophagic measures. The reported effect size in both models was described as comparable to injectable exenatide [1].
A Phase 1a blinded, placebo-controlled, randomized single- and multiple-ascending-dose study in healthy participants characterized oral pharmacokinetics, tolerability and pharmacodynamic markers across ascending dose cohorts [2].
ATTAIN-1, a multinational randomized double-blind Phase 3 trial, evaluated once-daily oral administration across three dose arms versus placebo over 72 weeks in participants with obesity and without diabetes. Percent change in body weight from baseline was the primary measure; investigators reported greater mean reduction in each active arm than in placebo, with gastrointestinal events the most commonly reported adverse events and discontinuation for adverse events rising across the arms [3].
A separate Phase 3 program in participants with early type 2 diabetes used glycemic endpoints as the primary measures and was reported in parallel [4].
Follow-on pharmacology work in Science Translational Medicine assembled receptor-level, cellular and in vivo data to describe the basis for non-peptide agonism at GLP-1R [5].
Combinations examined in the research literature. Descriptive only — not a recommendation to combine compounds.